|
5/2/2013 4:39:26 PM
|
Corcept Therapeutics Posts Q1 Loss Per Share Of $0.12 Vs. Loss $0.13 Year Ago
|
|
3/7/2013 5:09:14 PM
|
Corcept Therapeutics Posts Q4 Loss Per Share Of $0.11 Vs. Loss $0.12 Year Ago
|
|
2/12/2013 4:42:22 PM
|
Corcept Therapeutics Posts Q4 Net Revenue Of $1.4 Mln
|
|
10/31/2012 4:46:40 PM
|
Corcept Therapeutics Posts Q3 Loss Per Share Of $0.08, Same As Last Year
|
|
10/15/2012 9:03:40 AM
|
Corcept Therapeutics Announces Appointment Of Daniel Bradbury To Board
|
|
8/7/2012 8:58:03 AM
|
|
|
8/7/2012 8:51:45 AM
|
|
|
8/7/2012 8:44:20 AM
|
|
|
8/7/2012 8:36:13 AM
|
Corcept Therapeutics Announces $30 Mln Synthetic, Capped Royalty Transaction
|
|
8/7/2012 8:32:38 AM
|
Amended: Corcept Therapeutics Q2 Loss Per Share $0.09 Vs. Loss $0.11 Prior Year
|
|
7/2/2012 9:27:26 AM
|
|
|
7/2/2012 9:23:53 AM
|
Corcept Therapeutics Agrees To Sell 11 Mln Shares In Underwritten Public Offering
|
|
7/2/2012 7:25:57 AM
|
Corcept Therapeutics Offers To Issue And Sell 11 Mln Shares Of Common Stock In Public Offering
|
|
2/17/2012 7:35:02 PM
|
|
|
1/27/2012 8:23:54 AM
|
|
|
6/30/2011 8:12:51 AM
|
|